Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Torben Plesner
Daratumumab, lenalidomide, and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: MAIA final survival analysis
Abstract In previous analyses of MAIA, daratumumab plus lenalidomide/dexamethasone (D-Rd) significantly improved progression-free survival and overall survival (OS) versus lenalidomide/dexamethasone (Rd) in transplant-ineligible newly diagnosed multiple myeloma (NDMM). We report results on long-term OS and subsequent antimyeloma therapies from the MAIA final analysis. A protocol amendment (July 20, 2021) led to a long-term extension of MAIA, during which patients were followed for OS.
Sustained Improvement in Health‐Related Quality of Life in Transplant‐Ineligible Newly Diagnosed Multiple Myeloma Treated With Daratumumab, Lenalidomide, and Dexamethasone: MAIA Final Analysis of Patient‐Reported Outcomes
1 Introduction Daratumumab was the first anti-CD38 monoclonal antibody approved in newly diagnosed multiple myeloma (NDMM) and has demonstrated an overall survival benefit in three frontline regimens [1-5]. Although triplet and quadruplet regimens are associated with superior outcomes in the transplant-ineligible population compared with doublet therapy [2, 6, 7], they are less likely to be used in elderly and/or frail patients due to a perceived risk of treatment-related complications [8, 9].
Plain language summary of the MAIA study of daratumumab plus lenalidomide and dexamethasone for the treatment of people with newly diagnosed multiple myeloma | Future Oncology
Future OncologyAhead of Print Plain Language Summary of PublicationOpen Access , , , , , , , , , , , , , , , , , , , , , , & Abstract What is this summary about? This is a summary of a clinical trial called MAIA. The trial tested 2 combinations of cancer drugs (daratumumab plus lenalidomide and dexamethasone compared with lenalidomide and dexamethasone) in people with newly diagnosed multiple myeloma.
Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial
Summary Background In the primary analysis of the phase 3 MAIA trial (median follow-up 28·0 months), a significant improvement in progression-free survival was observed with daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in transplantation-ineligible patients with newly diagnosed multiple myeloma. Here, we report the updated efficacy and safety results from a prespecified interim analysis for overall survival.
Health-Related Quality of Life in Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma: Findings From the Phase III MAIA Trial
Aurore Perrot, MD, PhD1; Thierry Facon, MD2; Torben Plesner, MD3; Saad Z. Usmani, MD, PhD4; Shaji Kumar, MD5; Nizar J. Bahlis, MD6; Cyrille Hulin, MD7; Robert Z. Orlowski, MD, PhD8; Hareth Nahi, MD, PhD9; Peter Mollee, MBBS, FRCPA, FRACP, MMSc10; Karthik Ramasamy, MD, PhD11; Murielle Roussel, MD1; Arnaud Jaccard, MD, PhD12; Michel Delforge, MD, PhD13; Lionel Karlin, MD14; Bertrand Arnulf, MD, PhD15; Ajai Chari, MD16; Jianming He, PhD17; Kai Fai Ho, PhD18; Rian Van Rampelbergh, MD19; Clarissa M.
Daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma: final results from the phase 2 GEN501 and SIRIUS trials
Summary Background Daratumumab showed encouraging efficacy as monotherapy in patients with heavily pretreated multiple myeloma in the GEN501 and SIRIUS studies. Here we report a pooled, post-hoc final analysis of these two studies. Methods GEN501 was an open-label, multicentre, phase 1–2, dose escalation and expansion study done in the Netherlands, the USA, Sweden, and Denmark.
Prophylactic immunoglobulin therapy in secondary immune deficiency - an expert opinion
Introduction: In primary immunodeficiency (PID), immunoglobulin replacement therapy (IgRT) for infection prevention is well-established and supported by a wealth of clinical data. On the contrary, very little evidence-based data is available on the challenges surrounding the use of IgRT in secondary immune deficiencies (SID), and most published guidelines are mere extrapolations from the experience in PID.
Taylor & Francis Online
The number of patients with secondary immune deficiencies (SID) is on the rise, mostly since the arrival on the market of novel targeted therapies that have increased the survival rates of patients with hematological malignancies. The recent changes in the SID landscape have brought with them new and diverse medical needs that treatments for SID management should strive to meet.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Torben
Contact Torben, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack